surlorian

AssetAlso ARM210, S48168, RYCAL DMD

RYR1 channel stabilizer (calstabin/RyR stabilizer) preventing pathological calcium leak

Stage: Phase 2
Modality: Small molecule
Target: RYR1; 1
Indication: 1
Trial: 1
Developer

Indications

1

Autosomal dominant RYR1-Related myopathy
Phase 2, Recruiting, NCT07560020, clinicaltrials.gov, 7 Oct 2026

In the full profile

Targets and what it contains1
Owner and partners1
Trials1
Evidence for its targets1
Signals1

Every asset’s record: target, stage, trials and the evidence behind it.